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Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the world, and it comprises a spectrum of
hepatic abnormalities from simple hepatic steatosis to steatohepatitis, fibrosis, cirrhosis, and liver cancer. While the pathogenesis
of NAFLD remains incompletely understood, a multihit model has been proposed that accommodates causal factors from a
variety of sources, including intestinal and adipose proinflammatory stimuli acting on the liver simultaneously. Prior cellular and
molecular studies of patient and animal models have characterized several common pathogenic mechanisms of NAFLD, including
proinflammation cytokines, lipotoxicity, oxidative stress, and endoplasmic reticulum stress. In recent years, gut microbiota has
gained much attention, and dysbiosis is recognized as a crucial factor in NAFLD. Moreover, several genetic variants have been
identified through genome-wide association studies, particularly rs738409 (Ile748Met) in PNPLA3 and rs58542926 (Glu167Lys)
in TM6SF2, which are critical risk alleles of the disease. Although a high-fat diet and inactive lifestyles are typical risk factors
for NAFLD, the interplay between diet, gut microbiota, and genetic background is believed to be more important in the
development and progression of NAFLD. This review summarizes the common pathogenic mechanisms, the gut microbiota
relevant mechanisms, and the major genetic variants leading to NAFLD and its progression.

1. Introduction
Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the world. It is present in 30%
of the general adult population and found predominantly in
obese people with high-fat diets and inactive lifestyles. In
reality, NAFLD comprises a spectrum of hepatic abnormalities that are observable in liver histological slides, from a simple intrahepatic accumulation of fat (steatosis or nonalcoholic
fatty liver, NAFL) to various degrees of necrotic inflammation
(nonalcoholic steatohepatitis, NASH) [1–3]. Simple steatosis
(i.e., NAFL) rarely progresses to advanced disease whereas,
in approximately 20% of patients with NASH, it progresses
to fibrosis and cirrhosis and potentially to hepatocellular
carcinoma over a 15-year time period [4, 5]. The majority

of patients with NAFLD are obese or even morbidly obese
and have accompanying insulin resistance that plays a central
role in the metabolic syndrome [6–9]. Thus, NAFLD is also
deemed to be hepatic manifestation of metabolic syndrome
which is a cluster of complex conditions including central
obesity, hypertension, hyperglycaemia, hypertriglyceridemia,
and low HDL (high density lipoprotein) that are predictive
risk factors of cardiovascular disease, stroke, and diabetes
[10, 11].
NAFLD has been considered a condition with a “two-hit”
process of pathogenesis since 1998 when Day and James first
proposed this hypothesis [12] with evidence from the Berson
et al. study describing the role of lipid peroxidation in the
liver injury [13]. Essentially, the first hit is the development
of hepatic steatosis via accumulation of triglycerides in
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hepatocytes, which increases the vulnerability of the liver
to various possible “second hits” that in turn lead to the
inflammation, fibrosis, and cellular death characteristics of
NASH. The second hit can be a variety of factors, such as
oxidative stress, endoplasmic reticulum stress, proinflammatory cytokines, and gut-derived bacterial endotoxin. As it
has evidently emerged that (1) accumulation of triglycerides
in hepatocytes may be a protective mechanism from liver
damage and (2) hepatic inflammation can precede the simple
hepatic steatosis and can also be a cause of steatosis, it has
been believed that many “hit” factors may act simultaneously
leading to the development of NAFLD, which supports the
multihit model proposed in 2010 [14]. Indeed, among the
proposed hit factors, many can interact with each other,
forming a vicious circle. Recent advances in metagenomics
complicate the understanding of the pathogenesis of NAFLD
further in that dysbiosis and host-microbiota interactions
are now also implicated. Moreover, genome-wide association
studies have discovered several promising candidate genes,
serving as the genetic background for the disease. These
genetic players appear to distinguish subgroups of NFLD
patients from obese and insulin resistance associated populations. Although a high-fat diet and inactive lifestyles are
typical risk factors for NAFLD, the interplay between diet,
gut microbiota, and genetic background can play a crucial
role in the development and progression of NAFLD. This
review summarizes the common pathogenic mechanisms,
the gut microbiota relevant mechanisms, and the major
genetic variants leading to NAFLD and its progression (Figure 1).

2.1. Adipose Tissue Inflammation. What exactly initiates
adipose tissue inflammation in obesity is uncertain; but
hypoxia and death of rapidly expanding adipocytes are
believed to play a role [15]. Adipocytes under inflammation secrete cytokines and chemokines, particularly tumor
necrosis factor-𝛼 (TNF-𝛼), interleukin-6 (IL-6), and CCchemokine ligand-2 (CCL2) [15, 16]. TNF-𝛼 was the first
proinflammatory cytokine detected in adipose tissue and
is involved in the regulation of insulin resistance. Studies
indicated that neutralization of TNF-𝛼 activity by an antiTNF-𝛼 monoclonal antibody improves insulin resistance and
fatty liver disease in animals [17]. IL-6 is derived from many
cells throughout the body including adipocytes. Serum levels
of these cytokines correlate remarkably well with the presence
of insulin resistance, and adipose tissue-derived TNF-𝛼 and
IL-6 have been shown to regulate hepatic insulin resistance
via upregulation of SOCS3, a suppressor of cytokine signaling
[17]. CCL2 recruits macrophages to the adipose tissue, resulting in even more local cytokine production and perpetuating
the inflammatory cycle; TNF-𝛼 and IL-6 induce a state of
insulin resistance in adipocytes, which stimulates triglyceride
lipolysis and fatty acid release into the circulation. At the
same time, extrahepatic adipocytes are compromised in their
natural ability to secrete adiponectin, an anti-inflammatory
adipokine that facilitates the normal partitioning of lipid to
adipocytes for storage [18]. Circulating adiponectin regulates
hepatic fatty 𝛽-oxidation through AMP-activated protein
kinase (AMPK) and acetyl-CoA carboxylase (ACC) signaling
[19]. Together, these abnormalities accentuate fat loss from
adipocytes and promote ectopic fat accumulation.

2. Common Pathogenic Mechanisms
of NAFLD

2.2. De Novo Lipogenesis (DNL). Presumably lipogenesis in
liver could be increased due to the steatotic nature of NAFLD.
A number of prior studies have shown that diets enriched
in both saturated fat and simple sugar carry a high risk of
hepatic steatosis, at least in part, through enhanced DNL [20–
23]. The role of DNL in the development of hepatic steatosis is
further supported by a recent study in subjects with metabolic
syndrome and a high content of liver fat [24]. A 3-fold higher
rate of de novo fatty acid synthesis is seen in these subjects.
In addition, specific dietary compositions may have different effects. Basically since carbohydrates are substrates for
DNL, the amount of carbohydrate in the diet will positively
influence the amount of DNL in the liver. Simple sugars are
converted to fatty acids more readily than complex carbohydrates [25, 26], and fructose is a more potent inducer of DNL
than glucose [27, 28]. This is also supported by epidemiologic
evidence linking dietary fructose to hepatic steatosis and
NASH [20, 29]. It is worth noting that dietary fat, particularly
saturated fat, stimulates DNL by upregulating SREBP-1 (sterol
responsive element binding protein), a key regulator of the
lipogenic genes in the liver [30]. However, not all individuals
with hepatic steatosis had increased DNL nor upregulated
SREBP-1 expression, as observed in the Mancina et al. study
showing a paradoxical dissociation between hepatic DNL and
hepatic fat content due to the PNPLA3 148M allele [31].

Hepatic steatosis is a prerequisite to making a histological
diagnosis of NAFLD [2]. Several mechanisms may lead to
steatosis, including (1) increased fat supply such as high-fat
diet and excess adipose lipolysis; (2) decreased fat export
in the form of very low density lipoprotein-triglyceride; (3)
decreased free fatty 𝛽-oxidation; and (4) increased de novo
lipogenesis (DNL) [2]. Molecular mechanisms responsible
for the accumulation of fat in the liver are not fully understood; however, certain cytokines derived from inflammation
sites, particularly from extrahepatic adipose tissues, can
trigger this process. In addition, the enhancement of hepatic
DNL is deemed to be a unique feature in steatosis. More
importantly, insulin resistance appears to be at center stage
for the massive metabolic dysregulations of NAFLD that
initiate and aggravate hepatic steatosis. At a certain point,
the simple steatosis transforms to steatohepatitis in about
20–30% of NAFLD patients. This breakthrough-like process
is mediated by the interplay of multiple hit factors. Pathological features of NASH include simple hepatic steatosis
and, more characteristically, liver cell damage and accompanying inflammation and/or fibrosis. Currently, a number
of common pathogenic mechanisms have been proposed
and characterized for the transition from simple steatosis to
NASH, such as lipotoxicity, oxidative stress, mitochondrial
dysfunction, and endoplasmic reticulum stress.

2.3. Insulin Resistance. Studies have highlighted the fact that
insulin resistance is a characteristic feature of NAFLD [7–9]
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Figure 1: Overview at the pathogenesis of nonalcoholic fatty liver disease (NAFLD). The interplay between diet, microbiota, and host genetic
variants plays a crucial role in the complex pathogenesis of NAFLD through a variety of mechanisms. The NAFLD patients can now be
categorized into different populations based on their insulin sensitivity and genetic predisposition. Insulin resistance is at the center of the
NAFLD pathogenic process, and a number of key factors are involved in the development of NAFLD, such as diet, dysbiosis, gut-liver axis,
genetic predisposition genes (PNPLA3 and TM6SF2), oxidative stress, MDF (mitochondrial dysfunction), endoplasmic reticulum (ER) stress,
de novo lipogenesis, lipotoxicity, and proinflammatory cytokines.

and is caused by a variety of factors, including soluble mediators derived from immune cells and/or adipose tissue, such
as TNF-𝛼 and IL-6 [32]. Serine phosphorylation of insulin
receptor substrates by inflammatory signal transducers such
as c-jun N-terminal protein kinase 1 (JNK1) or inhibitor of
nuclear factor-𝜅B kinase-𝛽 (IKK-𝛽) is considered one of the
key aspects that disrupts insulin signaling [14]. On the other

hand, insulin resistant subjects with NAFLD show reduced
insulin sensitivity, not only at the level of the muscle, but also
at the level of the liver and adipose tissue [7–9, 33], which can
lead to a far more complex metabolic disturbance of lipid and
glucose. However, not all people with NAFLD have increased
insulin resistance, and NAFLD, per se, cannot be considered
a cause for insulin resistance but rather a consequence
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as shown by studies in subjects genetically predisposed to
NAFLD. Mutations in PNPLA3 (patatin-like phospholipase
domain containing 3) [34, 35], TM6SF2 (transmembrane 6
superfamily member 2) [6, 36], DGAT1 (diacylglycerol Oacyltransferase 1) [37], or hypobetalipoproteinemia [38, 39]
genes are not related to increased insulin resistance except for
severely obese individuals in which it is associated [40]. It is
worth noting that insulin resistance is characterized not only
by increased circulating insulin levels but also by increased
hepatic gluconeogenesis, impaired glucose uptake by muscle,
and increased release of free fatty acids and inflammatory
cytokines from peripheral adipose tissues [41], which are
the key factors promoting accumulation of liver fat and
progression of hepatic steatosis (Figure 1).
2.4. Lipotoxicity. Studies have indicated that certain lipids
can be harmful to hepatocytes in NAFLD. This is particularly
true of the long-chain saturated fatty acids (SFAs) such as
palmitate (C16:0) and stearate (C18:0), which are abundant in
animal fat and dairy products and produced in the liver from
dietary sugar. Under physiological conditions, SFAs are transported to mitochondria for 𝛽-oxidation or esterified for either
excretion in the form of VLDL (very low density lipoproteins)
or storage as lipid droplets. In the pathophysiology of NASH,
multiple mechanisms are concurrently operative to produce
liver injury in hepatocytes overwhelmed by SFA and by free
cholesterol (FC) from de novo synthesis [42, 43]. FC accumulation leads to liver injury through the activation of intracellular signaling pathways in Kupffer cells (KCs), hepatic stellate
cells (HSCs), and hepatocytes. The activation of KCs and
HSCs promotes inflammation and fibrogenesis [44]. These
lipids, including FC, SFA, and certain lipid intermediates
from excessive SFA, can activate a variety of intracellular
responses such as JNK1 and a mitochondrial death pathway,
resulting in lipotoxic stress in the endoplasmic reticulum and
mitochondria, respectively [42, 43, 45]. In addition, the tolllike receptor 4 (TLR4) is a pattern recognition receptor that
activates a proinflammatory signaling pathway in response to
excessive SFAs. This pathway is initiated by recruiting adaptor molecules such as toll/IL-1 receptor domain containing
adaptor protein (TIRAP) and myeloid differentiation factor
88 (MyD88) that ultimately lead to activation of nuclear factor
𝜅B with production of TNF-𝛼 [46].
2.5. Mitochondrial Dysfunction. Mitochondria are the most
important energy suppliers of the cell and play a pivotal
role in fatty acid metabolism. Fatty acid oxidation is able to
be upregulated to compensate for some degree of increased
deposition of fat; however, multiple studies have shown that
liver ATP levels are decreased in NAFLD [47–49]. This
discrepancy implicates mitochondrial dysfunction in the
state of liver fat overload that is characteristic of NAFLD.
Although the mechanisms responsible for the mitochondrial
dysfunction remain poorly understood in NAFLD, reduced
enzymatic activities of mitochondrial electron transport
chain (ETC) complexes may be attributed to increased
generation of reactive oxygen species (ROS) as a result of
ETC leakage during mitochondrial 𝛽-oxidation in energy
production (in the form of ATP) [50]. Studies have found that
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ROS can damage the ETC [51] and even cause mutations in
the mitochondria DNA [52].
2.6. Oxidative Stress. In the context of increased supply of
fatty acids to hepatocytes, oxidative stress can occur and
be attributable to raised levels of reactive oxygen/nitrogen
species (ROS/RNS) and lipid peroxidation that are generated
during free fatty acid metabolism in microsomes, peroxisomes, and mitochondria [53–55]. Peroxidation of plasma
and intracellular membranes may cause direct cell necrosis/apoptosis and megamitochondria, while ROS-induced
expression of Fas-ligand on hepatocytes may induce fratricidal cell death. Recent studies support the idea that oxidative
stress may be a primary cause of liver fat accumulation
and subsequent liver injury, and ROS may play a part even
in fibrosis development [56, 57]. Importantly, these species
can initiate lipid peroxidation by targeting polyunsaturated
fatty acids (PUFAs), resulting in the formation of highly
reactive aldehyde products, such as 4-hydroxy-2-nonenal (4HNE) and malondialdehyde (MDA). These reactive lipid
derivatives have the potential to amplify intracellular damage
by mediating the diffusion of ROS/RNS into the extracellular
space, thus causing tissue damage.
2.7. Endoplasmic Reticulum (ER) Stress. The ER is a vast
dynamic and tubular network responsible for the synthesis,
folding/repair, and trafficking of a wide range of proteins
[58]. Under pathological and/or stressful conditions such as
NASH, it has been observed that ER efficiency in the proteinfolding, repairing, and/or trafficking machinery is decreased
while the demand of protein synthesis and folding/repair is
increased [58, 59]. Such an imbalance between the load of
needed protein-folding and the response-related capability of
the ER is termed ER stress, which can lead to the accumulation of unfolded and/or misfolded proteins within the ER
lumen. This type of cellular stress usually triggers an adaptive
response, aimed at resolving ER stress, called unfolded protein response (UPR) [60–62]. The UPR is mediated by at least
three different stress-sensing pathways: protein kinase RNAlike ER kinase (PERK), inositol-requiring protein 1𝛼 (IRE1𝛼),
and activating transcription factor 6 (ATF6) [62]. Coupled
with inflammation, oxidative stress, insulin resistance, and
apoptosis signaling, hepatic ER stress seems to play an
important role in regulating the composition and size of
lipid droplets as well as lipid synthesis, including cholesterol
metabolism [58, 59, 63], through SREBP.

3. Microbiota Associated Mechanisms
of NAFLD
Gut microbiota was first found to be altered in patients with
chronic liver disease more than 80 years ago. Derangement
of the gut flora, in particular small intestinal bacterial
overgrowth (SIBO), occurs in a large percentage (20–75%)
of patients with chronic liver disease. In recent years, the
gut microbiome has gained much more attention due to
the advancement of the high-throughput next-generation
sequencing (NGS) technology. Prior studies of gut flora relied
on culture dependent techniques, which were labor intensive
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and limited only to a countable number of species, as over
80% of the gut microbes are not cultivatable [64]. In contrast,
NGS-based taxonomic assignments of the uncultured,
undefined microbes into operational taxonomic units
(OTUs) represent an effective and revolutionary approach
for studies on highly complex gut microbiota, which is based
on clustering of the 16S rRNA sequences derived from the
NGS platforms. This approach allows the characterization of
both composition and diversity of the intestinal microbiota.
According to evidence from relevant studies, the gut microbiota may contribute to the pathogenesis of NAFLD through
several mechanisms, including (1) increased production and
absorption of gut short-chain fatty acids; (2) altered dietary
choline metabolism by the microbiota; (3) altered bile acid
pools by the microbiota; (4) increased delivery of microbiotaderived ethanol to liver; (5) gut permeability alterations and
release of endotoxin; and (6) interaction between specific
diet and microbiota. Most recently, Musso et al. brought up a
new mechanism by that chronic kidney disease may mutually
aggravate NAFLD and associated metabolic disturbances
through multiple paths including altered intestinal barrier
function and microbiota composition [65]. In fact, diet can
affect the composition and diversity of gut microbiota; thus
any changes of gut microbiota that are observed in a dietstratified study should be interpreted with caution because
these changes could be either a direct effect of specific diets
or an indirect effect of the gut-liver interactive axis which
has been proposed and observed recently [66, 67].
3.1. Short-Chain Fatty Acids (SCFAs) Relevant Mechanisms.
In the intestine, SCFAs are produced in the distal small
intestine and colon where nondigestible carbohydrates
like resistant starch, dietary fiber, and other low-digestible
polysaccharides are fermented by saccharolytic bacteria
which include the phyla Bacteroidetes, Firmicutes, and
Actinobacteria. Acetate and propionate are the main products
of Bacteroidetes phylum and butyrate is mainly produced
by Firmicutes phylum. As an energy precursor, SCFAs are
implicated in the pathogenesis of NAFLD because of their
possible contribution to obesity. The first evidence regarding
SCFAs was from Turnbaugh et al. study [68] showing that
the cecum of ob/ob mice has an increased concentration of
SCFAs and that transplantation of germ-free mice with the
gut microbiome from ob/ob mice caused greater fat gain
than transplants from lean animals. In humans, increased
production of SCFAs by the gut microbiota was also observed
in overweight and obese people, compared to lean subjects
[69]. In metagenomics analysis, the majority of studies
showed that ob/ob mice [70] and obese patients [71] exhibit
reduced abundance of Bacteroidetes and proportionally
increased abundance of Firmicutes. However, how these
ratio changes affect energy imbalance leading to obesity
and its complications including NAFLD needs further
functional and species-level analyses. In fact, SCFAs have
more beneficial effects than their obesity-causing effects in
general [72]. Beneficial effects of SCFAs are through several
ways, such as immunoregulation, enhanced intestinal barrier
function, acting as a histone deacetylase 1 (HDAC) inhibitor
to decrease expression of lipogenic genes and to increase
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carnitine palmitoyltransferase 1A expression [72], and a
peroxisome proliferator-activated receptor-𝛾- (PPAR𝛾-)
dependent mechanism, shifting metabolism in adipose and
liver tissue from lipogenesis to fatty acid oxidation [73].
3.2. Dietary Choline Mechanism. Dietary choline is required
for very low density lipoprotein synthesis and hepatic lipid
export; and dietary choline-deficiency has been linked with a
variety of conditions including hepatic steatosis. Buchman et
al. [74] found that, in patients with parenteral nutrition, diets
deficient in choline can lead to increased hepatic steatosis,
which can be reversed with choline supplementation. This
study suggests a role of choline in fat export out of the
hepatocytes. Recent studies indicate a role of the intestinal
microbiota in the conversion of dietary choline to toxic
methylamine, a substance that not only mimics a cholinedeficient diet by decreasing effective choline levels but also
exposes the host to an inflammatory toxic metabolite [75].
Very recently, a metagenomic analysis of the microbial
communities living in the intestinal tracts of 15 women with
a choline-depleted diet revealed that increased Gammaproteobacteria abundance and decreased Erysipelotrichi abundance were protective against developing steatosis [76].
3.3. Bile Acid Pool Related Mechanisms. Within hepatocytes,
bile acids are synthesized from cholesterol through enzymatic
pathways and then conjugated with either glycine or taurine before secretion into bile and released into the small
intestine. In the small intestine, conjugated bile acids not
only assist in lipid absorption and transport but have also
been increasingly recognized to function as nuclear receptor
binders and to have a putative role in altering the microbiome
[77]. On the other hand, bacteria within the intestine can
also chemically modify bile acids and thereby alter the
composition of the bile acid pool [78, 79]. Besides the classic
role as detergents to facilitate fat absorption, bile acids have
also been recognized as important cell signaling molecules
regulating lipid metabolism, carbohydrate metabolism, and
inflammatory response [80]. These molecular functions are
mediated through their binding and activation of the nuclear
hormone receptor, farnesoid X receptor (FXR), and the G
protein coupled cell surface receptor TGR5 [81]. Intestinal
FXR activity upregulates endocrine FGF19 expression, which
inhibits hepatic bile acid synthesis via CYP7A1 signaling [82].
McMahan et al. showed that activation of bile acid receptors
with a receptor agonist was able to improve NAFLD histology
in an obese mouse model [83]. Due to the nature of the
complex interplay between the microbiome and the host bile
acid pool, further studies are required in the context of risk
for NAFLD and NASH.
3.4. Endogenous Alcohol Theory. The possible role for endogenous alcohol in NAFLD was first implicated in ob/ob mice.
Cope et al. found that alcohol in the breath of obese animals
is higher than that of lean animals [84], but they could
not find any difference in the breath alcohol concentration
between NASH patients and lean controls in a human study
[85]. Recently, Zhu et al. found that NASH patients exhibited
significantly elevated blood ethanol levels, while similar
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blood ethanol concentrations were observed between healthy
subjects and obese non-NASH patients [86]. Further, in
this metagenomics study, the composition of NASH microbiomes was found to be distinct from those of healthy and
obese microbiomes, and Escherichia stood out as the only
abundant genus that differed between NASH and obese
patients. Because Escherichia are ethanol producers, this finding is in agreement with their previous report that alcoholmetabolizing enzymes are upregulated in NASH livers [87].
However, Engstler et al. provided evidence against the alcohol
theory [88]. In their study, ethanol levels were similar in
portal vein and chyme obtained from different parts of the
GI tract between groups, while ethanol levels in vena cava
plasma were significantly higher in ob/ob mice, suggesting
that more ethanol was not metabolized in the liver due to
a significantly lower ADH activity observed in these ob/ob
mice. They proposed that increased blood ethanol levels in
patients with NAFLD may result from insulin-dependent
impairments of ADH activity in liver tissue, rather than from
an increased endogenous ethanol synthesis. Thus, the alcohol
theory currently faces conflicting results from different investigators. To clarify these conflicting results, de Medeiros and
de Lima have provided an interesting mechanistic framework
explaining how NAFLD might be an endogenous alcohol
fatty liver disease (EAFLD) [89]. However, this framework
requires experimental evidence to be validated.
3.5. Intestinal Permeability and Endotoxemia. The gut microbiota plays a part in maintaining the integrity of the intestinal
barrier [90]; and changes in the composition of microbiota
can lead to increased intestinal permeability and subsequent
overflow of harmful bacterial by-products to the liver that in
turn triggers hepatic inflammation and metabolic disorders.
Endotoxin, that is, lipopolysaccharide (LPS), is derived from
Gram-negative bacteria, and it has long been implicated in
chronic liver diseases. The first evidence in support of a role
for LPS in the pathogenesis of NASH was the observation
that endotoxemia readily induces steatohepatitis in obese
rats and mice [91]. Further, murine NAFLD models of
bacterial overgrowth develop compositional changes of the
gut microbiota and present increased intestinal permeability,
with a concurrent reduction in the expression of tight
junction proteins [92]. In human studies, Miele et al. found
evidence of a disruption in the intestinal barrier of biopsyproven NAFLD patients, along with an increased rate of
small bowel bacteria overgrowth, suggesting that alterations
in the microbiome may have contributed to disruption of gut
barrier integrity [93]. In addition, high-fat diets may facilitate
LPS uptake through elevated chylomicron production in
intestinal epithelial cells [94]. On the other hand, Yuan et al.
did not find the correlation between Gram-negative bacteria
abundance and the concentration of serum endotoxin and
there was no endotoxemia in the majority of pediatric
NASH patients [95], highlighting the multihit hypothesis
for the pathogenesis of NASH. Nonetheless, LPS and other
exogenous stimuli are responded to first by innate immunity through pattern recognition receptors such as toll-like
receptors (TLRs) and NOD-like receptors (NLRs). Although
TLRs might respond to nutritional lipids such as free fatty
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acids [96], studies have implicated the importance of LPSTLR4/TLR9 signaling in the pathogenesis of NAFLD. Both
TLR4- and TLR9-deficient mice are protected from high-fat
diet-induced inflammation and insulin resistance [97, 98],
while mice deficient in TLR5 develop all features of metabolic
syndrome including hyperphagia, obesity, insulin resistance,
pancreatic inflammation, and hepatic steatosis [99]. Metagenomic analysis indicated that TLR5 deficiency affected the
composition of the gut microbiota and, remarkably, transfer
of the microbiota from TLR5−/− mice to healthy mice
resulted in transfer of disease [99]. Moreover, Wlodarska
et al. found that NOD-like receptor family pyrin domain
containing 6 (NLRP6) inflammasome deficiency leads to an
altered transmissible, colitogenic gut microbiota [100]. When
fed with a methionine and choline-deficient diet (MCDD),
these inflammasome deficient mice developed NASH with
significantly higher severity than wild-type animals [101].
3.6. Saturated Fatty Acids. It has been well known that animal
meats are rich in saturated fatty acids (SFAs) which are
highly correlated to an increased risk of obesity, diabetes,
and cardiovascular diseases. Many studies have indicated that
saturated fatty acids are more toxic than their unsaturated
counterparts [102, 103]. It is worth noting that SFAs are
protective in alcohol induced fatty liver disease [104–106].
However, in liver and hepatocytes not exposed to alcohol,
SFAs appear to promote apoptosis and liver injury [107,
108]. It has been shown that SFAs increase the saturation of
membrane phospholipids, thus initiating unfolded protein
response (UPR) and leading to ER stress [108, 109]. SFAs
also affect mitochondrial metabolism and promote ROS
accumulation [23]. Furthermore, hepatocyte apoptosis has
been shown to be dependent on the activation of JNK
stress signaling pathways that respond to prolonged ER and
oxidative stress [109]. In addition, SFAs can interact with
gut microbiota to affect the progression of liver injury. For
instance, by analyzing changes in the intestinal metagenome
and metabolome of alcohol-fed mice, Chen et al. recently
found that synthesis of saturated long-chain fatty acid is significantly reduced when compared with normal-chew mice
and that supplementation of saturated long-chain fatty acids
recovers intestinal eubiosis and reduces ethanol-induced liver
injury in mice [110]. Moreover, de Wit et al. observed an
overflow of SFAs to the distal intestine in mice on a highSFA diet, which, rather than obesity itself, reduced microbial
diversity and increased the Firmicutes-to-Bacteroidetes ratio
in the intestine. Such a typical obesity microbiota profile
stimulated by SFAs favors the development of obesity and
hepatic steatosis [103].
3.7. Fructose. Fructose has been utilized as artificial sweetener in many commercial soft drinks that are consumed
largely by adolescents and in a variety of social circumstances. A number of studies have found that excess fructose
consumption is involved in the pathogenesis of NAFLD
and that upregulated de novo lipogenesis and inhibited fatty
acid 𝛽-oxidation are distinct metabolic processes for the
development of hepatic steatosis in individuals with NAFLD
[20, 24, 111–113]. Further, Abdelmalek et al. observed that
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increased fructose consumption is associated with a higher
fibrosis stage in patients with NAFLD, independent of age,
sex, BMI, and total calorie intake [29]. Using a fructoseinduced NAFLD mouse model, recent studies with metagenomics analysis found that fructose significantly decreased
Bifidobacterium and Lactobacillus and tended to increase
endotoxemia [114, 115]. Several probiotic bacterial strains of
Lactobacillus protect mice from the development of highfructose-induced NAFLD [116–118]. In addition, increased
expression of TLRs has been implicated in the development
of fructose-induced hepatic steatosis [119].

4. Genetic Background of NAFLD
Genomic variations that have a causative effect on the
development of human diseases can be divided into two
groups: ones in rare diseases and ones in common diseases.
The former follow Mendelian inheritance patterns that are
characterized by a single, highly penetrant but uncommon
mutation in a specific gene being necessary and sufficient
to cause the disease. The latter consist of causative mutations that are not subject to negative selection pressures,
and disease susceptibility is due to the combined effects of
multiple relatively common causative polymorphisms (minor
allele frequency 1–5%) that are carried by affected individuals.
Like most common diseases, NAFLD has been implicated
in an inherited component to susceptibility, meaning that
genetic variation does influence disease risk. As reviewed
by Macaluso et al. in 2015 [120], dozens of genes with
multiple polymorphisms have been discovered in genomewide association studies (GWAS) that may be responsible for
risk of NAFLD in certain populations. It is believed that as
more large scale GWAS are complete, more genes could be
identified. For instance, in early 2016 while we were preparing
this review, a novel variant MBOAT7 rs641738 was reported
to be associated with the development and severity of NAFLD
in individuals of European descent [121]. Among all reported
genes, only two of them (PNPLA3 and TM6SF2) have been
identified as potential genetic modifiers in more than one
large scale study [120, 122], which are the focus of our review.
According to genotypes in those key genes and sensitivity
to insulin, NAFLD patients can be categorized into different
subpopulations (Figure 1).
4.1. PNPLA3 (Patatin-Like Phospholipase Domain Containing
3). The PNPLA3 gene (adiponutrin) encodes a transmembrane polypeptide chain exhibiting triglyceride hydrolase
activity [123], which is highly expressed on the endoplasmic
reticulum and lipid membranes of hepatocytes and adipose
tissue [124]. It is also reported that PNPLA3 is highly
expressed in human stellate cells. The encoded protein has
retinyl esterase activity and allows retinol secretion from
hepatic stellate cells while the mutation causes intracellular
retention of this compound [125–127]. As the first genomewide association study with strong evidence for NAFLD, a
report from Romeo et al. in 2008 showed that a genetic variant, an allele in PNPLA3 (rs738409[G], encoding Ile148Met),
confers susceptibility to the disease in individuals of several
western populations [128]. This genetic variant was associated
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with increased liver fat and hepatic inflammation and fibrosis.
This finding has subsequently been reproduced with solid
evidence as shown in a meta-analysis comprising 16 studies
[129]. Compared with noncarriers, homozygous carriers of
the variant had a 73% higher liver fat content, a 3.2-fold
greater risk of high necroinflammatory scores, and a 3.2-fold
greater risk of developing fibrosis. The association between
the PNPLA3 variant and steatosis or severity of histological
liver disease has been widely observed in the majority of subsequent genome-wide association studies [130] and several
case-control studies, including those in Chinese, Korean, and
Japanese populations [131–133]. It is worth noting that the link
between PNPLA3 I148M variant and NAFLD is independent
of metabolic syndrome (MS) and its features; that is, most of
patients carrying this variant are not associated with obesity,
diabetes, and atherogenic dyslipidemia, as demonstrated in
the recent meta-analysis [129]. Furthermore, the PNPLA3
genotype seems to also influence steatosis development in
patients with hepatitis B and hepatitis C and alcohol abuse,
and it has been independently associated with the progression
of hepatitis, including fibrosis, cirrhosis, and HCC occurrence [134–136]. The association between the PNPLA3 variant
I148M and the risk of HCC development has been robustly
validated in patients with NAFLD [137, 138], and it has
been estimated that the homozygous carriers of the p.148M
mutation carry a 12-fold increased HCC risk as compared
to p.I148 homozygotes [139]. Finally, as described earlier,
subpopulations of NAFLD patients with PNLA3 mutation
are not associated with insulin resistance, a hallmark of
metabolic syndrome. Collectively, it seems that a distinct
entity might exist in which the PNPLA3 risk allele appears
to be a major driver of disease progression in combination
with viral infection, alcohol abuse, lifestyle (unhealthy diet
and inactivity), and/or nonlifestyle (cryptogenic) causes, for
example, PNPLA3-associated steatohepatitis (“PASH”) [140].
4.2. TM6SF2 (Transmembrane 6 Superfamily Member 2).
Another widely validated and intriguing genetic player in
NAFLD is the nonsynonymous variant rs58542926 (c.449
C>T) within the TM6SF2 gene at the 19p13.11 locus, which
encodes an E167K amino acid substitution. The role of variant
E167K in TM6SF2 was first described by Kozlitina et al.
[36] in an exome-wide association study in a multiethnic,
population-based cohort, highlighting the association of the
TM6SF2 variant with higher serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels—
as surrogates for NASH—and with reduced plasma levels of
triglycerides and low density lipoprotein- (LDL-) cholesterol.
In addition, they performed a functional analysis for TM6SF2
in mouse models by silencing the gene via adeno-associated
viral vectors. Silencing of the gene showed a 3-fold increase
in hepatic triglycerides levels and a decrease in plasma levels
of triglycerides, LDL- and high density lipoprotein- (HDL-)
cholesterols, and very low density lipoprotein (VLDL). Overall, their results demonstrated that the TM6SF2 gene regulated hepatic triglyceride secretion and that the functional
impairment of TM6SF2 promoted NAFLD. An association
between the TM6SF2 rs58542926 SNP and the severity of liver
disease has also been found in patients with biopsy-proven
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NAFLD in a recent study reported by Liu et al. [141].
More intriguingly, the E167K variant in TM6SF2 seems
able to disconnect the risk of NAFLD/NASH progression
from cardiovascular risk, which is supported mainly by the
Dongiovanni et al. study [142] showing that 188 (13%) out
of 1201 subjects who underwent liver biopsy for suspected
NASH were carriers of the E167K variant and that these
carriers had lower serum lipid levels than noncarriers, more
severe steatosis, necroinflammation, ballooning, and fibrosis
and were more likely to have NASH and advanced fibrosis
after adjusting for metabolic factors and the PNPLA3 I148M
risk variant. In addition, E167K carriers had lower risk of
developing carotid plaque; and in Swedish obese subjects
assessed for cardiovascular outcomes, E167K carriers had
higher ALT and lower lipid levels but also a lower incidence of
cardiovascular events. Consequently, carriers of the TM6SF2
E167K variant seem to be more at risk for progressive
NASH, but at the same time they could be protected against
cardiovascular diseases [143].

5. Interplay between Diet, Microbiota,
and Host Genetics
One of the biggest lessons we learned from the metagenomic
studies so far is that constitutive profiles of gut microbiota
can determine liver pathology in response to a high-fat diet
(HFD) in mice, reflecting a kind of interactive effect between
diet and gut microbiota, that is, a net effect after the interplay.
For instance, in a transplantation experiment [144], Le Roy
et al. selected donor mice at first, based on their responses
to a HFD. The “responders” developed hyperglycaemia
and had a high plasma concentration of proinflammatory
cytokines, and the “nonresponders” were normoglycaemic
and had a lower level of systemic inflammation, although
both developed comparable obesity on the HFD. Germ-free
mice were then colonized with intestinal microbiota from
either the responder or the nonresponder mice and then fed
the same HFD. The responder-receiver (RR) group developed fasting hyperglycaemia and insulinaemia, whereas the
nonresponder-receiver (NRR) group remained normoglycaemic. In contrast to NRR mice, RR mice developed hepatic
macrovesicular steatosis, which was confirmed by a higher
liver concentration of triglycerides and increased expression
of genes involved in de novo lipogenesis. Pyrosequencing of
the 16S ribosomal RNA genes revealed that RR and NRR
mice had distinct gut microbiota including differences at the
phylum, genera, and species levels. These results suggest that
the gut microbiota can contribute to the development of
NAFLD, independent of obesity but acting like a constitutional background of a host organ system. The interrelationship between diet, gut microbiota, and host genetics has been
unraveled further in a recent study reported by Ussar and
coworkers [145]. In this study, they utilized three commonly
used inbred strains of mice: obesity/diabetes-prone C57Bl/6J,
obesity/diabetes-resistant 129S1/SvImJ, and obesity-prone but
diabetes-resistant 129S6/SvEvTac mice. Analysis of metabolic
parameters and gut microbiota in all strains and their environmentally normalized derivatives revealed strong interactions between microbiota, diet, breeding site, and metabolic
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phenotype. More intriguingly, environmental reprogramming of microbiota resulted in obesity-prone 129S6/SvEvTac
mice becoming obesity resistant. This study suggests that
development of obesity/metabolic syndrome is the result of
interactions between gut microbiota, host genetics, and diet.

6. Conclusions
NAFLD is best considered a multietiology disease trait,
meaning that it is not caused by a single gene mutation
genetically and is not associated with only a single factor
environmentally; but it is the outcome of genetic variantenvironmental factor interplay determining disease phenotype and progression. The genetic variants in PNPLA3 and
TM6SF2 are only responsible for ∼50% of NAFLD patients
[120], and majority of PNPLA3-associated NAFLD patients
are not obese and have no insulin resistance and its related
diabetes and cardiovascular diseases [140]. In fact, like many
common diseases, NAFLD is polygenic, where the heritable
component to susceptibility variously accounts for up to 30–
50% of relative risk [130]. Moreover, individual environmental factors, particularly the specific diets, interact with gut
microbiota up front before a final beneficial or damaging
signal is sent. Whether environmental factors, including
lifestyle, are the cause of NAFLD will be steered by the
interaction with the host genetics as well as the constitutional
profile of gut microbiota. Thus, careful, multifaceted study
designs are warranted in future analysis in order to “catch”
the true causes to NAFLD.
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